Research

Hormonal

GLP-1 receptor agonists (semaglutide, tirzepatide) can cause excessive appetite suppression leading to restrictive eating behaviors, severe food aversion, dehydration, and acute kidney injury when used without intensive clinical monitoring.

If you are taking GLP-1 agonists (like Ozempic or Mounjaro), do not use them without regular medical supervision. Watch for signs of extreme food aversion, dehydration, or rapid weight loss. If you experience severe side effects like kidney issues or inability to eat, contact your doctor immediately. These drugs are powerful and require monitoring, especially if you have a history of eating disorders or have had bariatric surgery.

ModerateQualifiesMEDIUM confidence
Our clinical experience warns of a need for intensive monitoring and deeper understanding, as their potent efficacy could also inadvertently lead to extreme dietary restriction and weight loss in some patients.
Jesse R. Richards et al. · Obesity Reviews · 2024

Why this rating

Based on case series and clinical observation rather than large-scale RCTs specifically focused on adverse eating behaviors.

Source

Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss

Jesse R. Richards et al. · Obesity Reviews · 2024

DOI 10.1111/obr.13709

case_seriesCited 28×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →